Xiflox Drug Interactions

Film-coated tablet: Antacids, Minerals, and multivitamins: Concomitant ingestion of Moxifloxacin together antacids, minerals and multivitamins may result in impaired absorption of moxifloxacin after oral administration due to formation of chelate complexes with the multi-valent cations contained in these preparations. This may lead to plasma concentrations considerably lower than desired. Hence, antacids, anti-retroviral drugs (e.g. didanosine), and other preparations containing magnesium or aluminum, sucralfate and agents containing iron or zinc should be administered at least 4 hours before or 2 hours after ingestion of an oral moxifloxacin dose.
Moxifloxacin increases Cmax of digoxin by approximately 30 % at steady state without affecting AUC or trough levels.
Concomitant administration of charcoal with an oral dose of 400 mg moxifloxacin leads to a pronounced prevention of drug absorption and a reduced systemic availability of the drug by more than 80%. Therefore, the concomitant use of these two drugs is not recommended (except for overdose cases).
The prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests should be closely monitored if a quinolone is administered concomitantly with warfarin or its derivatives.
Concomitant administration of NSAIDs with quinolones may increase the risks of CNS stimulation and convulsions.
Solution for injection: Anticoagulants: Concomitant administration of anticoagulants with moxifloxacin may cause an increase in the anticoagulant activity. Therefore, INR monitoring should be performed and if necessary, the oral anticoagulant dosage should be adjusted as appropriate.
Nonsteroidal anti-inflammatory drugs (NSAIDs): The concomitant administration of an NSAID with a quinolone may increase the risks of CNS stimulation and convulsions.
Cisapride, erythromycin, anti-psychotics and tricyclic antidepressants: An additive effect of moxifloxacin and drugs that prolong the QT interval such as cisapride, erythromycin, anti-psychotics and tricyclic antidepressants cannot be excluded; therefore moxifloxacin should be used with caution when given concurrently with these drugs.
Morphine: Parental administration of morphine with moxifloxacin did not reduce the oral bioavailability of moxifloxacin and only slightly decreased Cmax (17%).
Atenolol: The pharmacokinetics of atenolol are not significantly altered by moxifloxacin. Following single dose administration in healthy subjects AUC was marginally increased (by approximately 4%) and peak concentrations were decreased by 10%.
Digoxin: The pharmacokinetics of digoxin are not significantly influenced by moxifloxacin and vice versa. After repeated dosing in healthy volunteers, moxifloxacin increased Cmax of digoxin by approximately 30% at steady state without affecting AUC or trough levels.